AZD9550 / AstraZeneca - LARVOL DELTA

This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight (clinicaltrials.gov) - P2 | N=14 | Active, not recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Active, not recruiting | N=871 ➔ 14

Enrollment change • Enrollment closed • Genetic Disorders • Obesity

CONTEMPO: A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight (clinicaltrials.gov) - P1/2 | N=166 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed • Monotherapy • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • DPP4

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Dec 2026 ➔ Jul 2027 | Trial primary completion date: Dec 2026 ➔ Jul 2027

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

ASCEND: A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone (clinicaltrials.gov) - P2 | N=377 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

CONTEMPO: A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight (clinicaltrials.gov) - P1/2 | N=160 | Recruiting | Sponsor: AstraZeneca | Active, not recruiting ➔ Recruiting | N=118 ➔ 160

Enrollment change • Enrollment open • Monotherapy • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • DPP4

Safety and pharmacokinetics of AZD9550, a GLP-1R/GCGR dual agonist, in a first-in-human study (ECO 2026) - "In healthy participants, including participants of Japanese descent, there were no safety concerns with single dose administration of AZD9550. AZD9550 is a once-weekly investigational drug for obesity with an optimized ratio of glucagon and GLP-1R agonism to maximize weight loss and end-organ protection. Conflicts of Interest & Funding: PS, SW, JN, EW, HY, KN, ERC, AS, DH and LH are employees and stockholders of AstraZeneca"

Clinical • First-in-human • P1 data • PK/PD data • Genetic Disorders • Obesity

A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234 (clinicaltrials.gov) - P1 | N=28 | Recruiting | Sponsor: AstraZeneca

New P1 trial • Hepatology

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: AstraZeneca | N=75 ➔ 50

Enrollment change • Genetic Disorders • Obesity

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity (clinicaltrials.gov) - P1 | N=75 | Recruiting | Sponsor: AstraZeneca | N=50 ➔ 75

Enrollment change • Genetic Disorders • Obesity

...AstraZeneca’s broader weight loss portfolio also includes the long-acting amylin AZD6234, which is due to read out phase 2 data in the first half of 2026. (FierceBiotech) - "Meanwhile, a phase 2 study of a combination of AZD6234 with the dual GLP-1 and glucagon agonist AZD9550 is due to read out in the second half of the year."

P2 data • Obesity

A Study to Investigate the Effect of AZD6234 and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Jul 2026 ➔ Dec 2026 | Trial primary completion date: Jul 2026 ➔ Dec 2026

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

CONTEMPO: A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight (clinicaltrials.gov) - P1/2 | N=118 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting | Trial completion date: Jul 2026 ➔ Mar 2027 | Trial primary completion date: Jul 2026 ➔ Mar 2027

Enrollment closed • Monotherapy • Trial completion date • Trial primary completion date • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • DPP4

A Study to Investigate the Effect of AZD6234 and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Jan 2026 ➔ Jul 2026 | Trial primary completion date: Jan 2026 ➔ Jul 2026

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

ASCEND: A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone (clinicaltrials.gov) - P2 | N=377 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

CONTEMPO: A Trial to Learn How Safe AZD9550 is in People With or Without Type 2 Diabetes Who Are Overweight or Obese (clinicaltrials.gov) - P1/2 | N=116 | Recruiting | Sponsor: AstraZeneca | N=88 ➔ 116 | Active, not recruiting ➔ Recruiting

Enrollment change • Enrollment open • Diabetes • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity • Type 2 Diabetes Mellitus

A Study to Investigate the Effect of AZD6234 and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: AstraZeneca | N=25 ➔ 50

Enrollment change • Genetic Disorders • Obesity

This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity/Overweight (clinicaltrials.gov) - P2 | N=871 | Recruiting | Sponsor: AstraZeneca

New P2 trial • Genetic Disorders • Obesity

CONTEMPO: A Trial to Learn How Safe AZD9550 is in People With or Without Type 2 Diabetes Who Are Overweight or Obese (clinicaltrials.gov) - P1/2 | N=88 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting | Trial completion date: May 2025 ➔ Jul 2026 | Trial primary completion date: May 2025 ➔ Jul 2026

Enrollment closed • Trial completion date • Trial primary completion date • Diabetes • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity • Type 2 Diabetes Mellitus

ASCEND: A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone (clinicaltrials.gov) - P2 | N=360 | Recruiting | Sponsor: AstraZeneca

New P2 trial • Genetic Disorders • Obesity

Safety and Pharmacokinetics of AZD9550, a GLP-1R/GCGR Dual Agonist, in a First-in-Human Study (OBESITY WEEK 2024) - "Background: Cotadutide was a synthetic once-daily GLP-1R/GCGR dual peptide agonist with a relative potency ratio of approximately 5:1... AZD9550 led to dose-dependent reductions in body weight in obese mice. In healthy participants, there were no safety or tolerability concerns with a pharmacokinetic profile supporting once-weekly dosing. AZD9550 is a novel, investigational drug for obesity with an optimized ratio of glucagon and GLP-1R agonism that is being studied further as a treatment to maximize weight loss and end-organ protection."

Clinical • P1 data • PK/PD data • Genetic Disorders • Obesity • Pain

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants (clinicaltrials.gov) - P1 | N=48 | Completed | Sponsor: AstraZeneca | Recruiting ➔ Completed

Trial completion • Hepatology • Non-alcoholic Steatohepatitis

CONTEMPO: A Trial to Learn How Safe AZD9550 is in People With Type 2 Diabetes Who Are Overweight or Obese (clinicaltrials.gov) - P1/2 | N=88 | Recruiting | Sponsor: AstraZeneca

New P1/2 trial • Diabetes • Hepatology • Metabolic Disorders • Non-alcoholic Steatohepatitis • Obesity • Type 2 Diabetes Mellitus

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatology • Non-alcoholic Steatohepatitis

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants (clinicaltrials.gov) - P1 | N=64 | Not yet recruiting | Sponsor: AstraZeneca

New P1 trial • Hepatology • Non-alcoholic Steatohepatitis